HOME >> BIOLOGY >> NEWS
New strategy for treating allergic disorders

Ghent − Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders. VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX − a spin-off from VIB and Ghent University − is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our bodys own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treat
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Aug-2007


Page: 1 2

Related biology news :

1. Does EPA have an adequate strategy to oversee nanotechnologies?
2. High blood pressure medication strategy proves effective in Hispanic women
3. Rutgers: GM/GMO/Biotech crop containment strategy
4. Scientists identify new strategy for preventing acute and chronic brain disease
5. International risk research strategy and funding needed for nanotech safety
6. Study shows metabolic strategy of stressed cell
7. Trojan horse strategy defeats drug-resistant bacteria
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Drug strategy makes cancer genes get lost in translation
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New strategy for treating allergic disorders

(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
(Date:10/22/2014)... and BOSTON , Oct. 22, 2014 ... leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical ... exclusive option to acquire Rhythm,s wholly owned subsidiary, Rhythm ... ghrelin agonist, for the treatment of diabetic gastroparesis and ... completed a successful Phase 2 trial of relamorelin for ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
Cached News: